Enzymatically Cleavable VAGGFG Linker for Eribulin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in achieving efficient toxin release due to the complex structure and hydrophilicity of Eribulin, which affects the therapeutic window and can lead to off-target toxicity, and existing linkers like PEG are complex to synthesize and have minimal light absorption.
Innovation Solution
The use of a novel enzymatically cleavable linker, VAGGFG, to conjugate Eribulin, enhancing drug release efficiency and tumor cell killing potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If PEG linkers are used to conjugate Eribulin, then hydrophilicity and stability are improved, but synthesis complexity increases and light absorption is minimal
Solution Approach 1:
The patent changes the chemical composition parameters of the linker from PEG-based to peptide-based (VAGGFG sequence), transforming the molecular structure to achieve both stability and ease of synthesis. This parameter change allows the linker to maintain stability while being more straightforward to manufacture through standard peptide synthesis methods.
Solution Approach 2:
The patent creates a composite linker structure combining Valine-Alanine-Glycine-Glycine-Pheylalanine-Glycine (VAGGFG) amino acid sequence with cleavable bonds, forming a hybrid material that integrates the stability of peptide structures with the functionality of cleavable linkers, resolving the contradiction between stability and synthesis complexity.
2Reliability
If existing polypeptide linkers (VC, VA, GGFG) are used, then enzymatic cleavage is achieved, but drug release efficiency is insufficient due to Eribulin's complex structure
Solution Approach 1:
The patent applies local quality by designing specific regions within the linker with different functions: the VAGGFG sequence provides enzymatic recognition and cleavage sites, while adjacent regions are optimized for Eribulin conjugation and stability. This localized functional differentiation enables both reliable enzymatic cleavage and efficient drug release despite Eribulin's complex structure.
Solution Approach 2:
The linker is segmented into distinct functional modules: N-terminal conjugation region, central VAGGFG cleavable sequence, and C-terminal drug attachment region. This segmentation allows each segment to independently perform its function, improving overall drug release efficiency while maintaining enzymatic cleavage capability.
3Quantity of substance
If Eribulin is conjugated to antibodies, then targeted delivery is achieved, but off-target toxicity occurs due to premature toxin release
Solution Approach 1:
The VAGGFG peptide linker serves as an intermediary between the antibody and Eribulin toxin, providing a stable connection during circulation while enabling controlled release at the target site. This intermediary function prevents premature toxin release that causes off-target toxicity, while maintaining the targeted delivery capability of the antibody-Eribulin conjugate.
Solution Approach 2:
The linker is pre-designed with cathepsin cleavage sites in the VAGGFG sequence, preparing the conjugate for controlled activation only after reaching the target tumor cells. This preliminary structural preparation ensures that toxin release is delayed until appropriate, preventing off-target effects during blood circulation while maintaining targeted delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VAGGFG linker improves drug release efficiency and tumor cell killing efficacy, offering a promising solution for ligand-drug conjugates with improved therapeutic outcomes.
Implementation Method 1
These polypeptides can be cleaved by cathepsins within tumor cells, releasing the toxins and thereby exerting antitumor effects
Data Source
Figure 1
Figure 2A~2E
Figure 2F~3
AI summary
The present disclosure relates to the technical field of biomedicines, in particular, relates to an enzymatically cleavable linker and a ligand-eribulin conjugate containing same, and more specifically, relates to the use of VAGGFG as an enzymatically cleavable linker.